The variability in results may result from the heterogeneity of anti-GAD disorders, suggesting that RTX may benefit only specific subgroups of patients, with factors such as the subjective nature of symptoms, frequent fluctuations, behavioral symptoms, and different pathogenic mechanisms contributing to varying treatment responses in SPS. This evidence concerns the gene GAD1 and stiff-person syndrome.